Search results for "interferon"

showing 10 items of 963 documents

T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice

2015

Background & Aims Cancer therapies are being developed based on our ability to direct T cells against tumor antigens. Glypican-3 (GPC3) is expressed by 75% of all hepatocellular carcinomas (HCC), but not in healthy liver tissue or other organs. We aimed to generate T cells with GPC3-specific receptors that recognize HCC and used them to eliminate GPC3-expressing xenograft tumors grown from human HCC cells in mice. Methods We used mass spectrometry to obtain a comprehensive peptidome from GPC3-expressing hepatoma cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identify immunodominant peptides. To circumvent GPC3 tolerance resulting from feta…

Cytotoxicity ImmunologicCancer Immunotherapy ; Immune Response ; Liver Cancer ; Tumor-associated AntigensCarcinoma HepatocellularTime FactorsCell SurvivalMice SCIDCD8-Positive T-LymphocytesBiologyLymphocyte ActivationTransfectionImmunotherapy AdoptiveInterferon-gammaInterleukin 21GlypicansHLA-A2 AntigenAnimalsHumansCytotoxic T cellIL-2 receptorAntigen-presenting cellInterleukin 3HepatologyImmunodominant EpitopesZAP70Liver NeoplasmsGastroenterologyDendritic CellsHep G2 CellsNatural killer T cellXenograft Model Antitumor AssaysMolecular biologyCoculture TechniquesGenes T-Cell ReceptorInterleukin 12FemaleGenetic Engineering
researchProduct

Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A

1999

Peptides derived from the melanoma-associated MART-1/Melan-A antigen are currently implemented in immunotherapy for inducing or augmenting T-cell responses directed against peptides expressed by autologous tumor cells in HLA-A2+ patients with melanoma. Here, we describe the specificity of the T-cell clone SK29-FFM1.1, which secretes GM-CSF in response to a panel of synthetic MART-1/Melan-A-derived peptides, including the naturally presented ILTVILGVL32–40, but exhibits cytotoxicity and IFN-γ secretion exclusively to the MART-1/Melan-A derived peptide AAGIGILTV27–35. In addition, cytotoxic T-lymphocyte (CTL) clone SK29-FFM1.1 recognizes 3 different naturally processed and presented peptides …

Cytotoxicity ImmunologicCancer ResearchCellular immunityReceptors Antigen T-Cell alpha-betaT-Lymphocytesmedicine.medical_treatmentBiologyTransfectionEpitopeInterferon-gammaMART-1 AntigenImmune systemAntigenAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedmedicineHumansProtein IsoformsCytotoxic T cellAmino Acid SequenceMelanomaneoplasmsintegumentary systemReverse Transcriptase Polymerase Chain ReactionImmunotherapyMolecular biologyRecombinant ProteinsClone CellsNeoplasm ProteinsCTL*OncologyImmunologyClone (B-cell biology)T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells

2019

Background/aim Cytokine-induced killer (CIK) cells are ex vivo expanded major histocompatibility complex (MHC)-unrestricted cytotoxic cells with promising effects against a variety of cancer types. Regulatory T-cells (T-reg) have been shown to reduce the effectiveness of CIK cells against tumor cells. Peptide P60 has been shown to inhibit the immunosuppressive functions of T-regs. This study aimed at examining the effect of p60 on CIK cells efficacy against renal and pancreatic cancer cells. Materials and methods The effect of P60 on CIK cytotoxicity was examined using flow cytometry, WST-8-based cell viability assay and interferon γ (IFNγ) ELISA. Results P60 treatment resulted in a signifi…

Cytotoxicity ImmunologicCancer ResearchFOXP3Cell SurvivalImmunotherapy.KidneyMajor histocompatibility complexT-Lymphocytes RegulatoryInterferon-gamma03 medical and health sciencesCytokine-Induced Killer Cells0302 clinical medicineCytokine-induced killer (CIK) cellCell Line TumorPancreatic cancermedicineHumansCytotoxic T cellViability assayCytotoxicityPancreasCancerCytokine-induced killer cellbiologyChemistryFOXP3Forkhead Transcription FactorsGeneral Medicinemedicine.diseaseCoculture TechniquesKidney NeoplasmsPancreatic NeoplasmsOncologyCell culture030220 oncology & carcinogenesisAdoptive cell transferCancer researchbiology.proteinCytokinesPeptidesAnticancer Research
researchProduct

In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immun…

1993

In order to understand further the effects of Newcastle-disease-virus(NDV)-modified tumour vaccines we investigated the feasibility of isolating lymphocytes from the site of injection of patients undergoing postoperative active specific immunization (ASI) with autologous NDV-modified tumour cells. Delayed-type-hypersensitivity(DTH)-like reactions from five cancer patients were surgically removed, minced and the tissue particles were digested with collagenase and DNase. Lymphoid cells recovered were expanded in a highly efficient limiting-dilution analysis system optimized for T cell growth [Moretta et al. (1983) J Exp Med 157: 743] and lymphocyte microcultures (clonal probability > 0.8) cou…

Cytotoxicity ImmunologicCancer ResearchT-LymphocytesT cellLymphocyteImmunologyNewcastle disease virusBiologyActive immunizationImmunophenotypingImmunophenotypingNeoplasmsmedicineHumansImmunology and AllergyHypersensitivity DelayedInterferon gammaCells CulturedVaccinationT lymphocytemedicine.anatomical_structureOncologyImmunizationDelayed hypersensitivityImmunologyCytokinesmedicine.drugCancer Immunology Immunotherapy
researchProduct

A continuous infusion of a minor histocompatibility antigen-immunodominant peptide induces a delay of male skin graft rejection.

2009

Abstract We previously reported that an inhibition of antigen-specific Interferon-γ release and cytotoxicity occurs after a continuous infusion of an HY immunodominant peptide although this treatment is not able to cause a significant delay of male skin grafts rejection. In vivo administration of high doses of an HY peptide, through mini-osmotic pumps, in naive female mice was used to study the effects on the male skin grafts rejection. A continuous infusion of 1 mg of an HY peptide induces a significant delay of male skin graft rejection. In vitro HY-specific Interferon-γ release was inhibited adding peptide-specific suppressor cells: the ability to inhibit Interferon-γ release was evident…

Cytotoxicity ImmunologicGraft RejectionMaleImmunologyAntigen presentationH-Y AntigenPharmacologyCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryMinor Histocompatibility AntigensInterferon-gammaMiceImmune systemMinor Histocompatibility antigenInterferonMinor histocompatibility antigenmedicineImmunology and AllergyAnimalsSuppressor cellInfusion PumpsSettore MED/04 - Patologia GeneraleImmunosuppression TherapyAntigen PresentationRodentCD40biologyImmunodominant EpitopesT-cell receptorCD28Forkhead Transcription FactorsHematologyDendritic CellsSkin TransplantationPeptide FragmentsAntigen presentation; Minor Histocompatibility antigen; graft rejection; Suppressor cells; RodentMice Inbred C57BLImmunologybiology.proteinB7-1 AntigenFemaleE-SelectinCD8medicine.drugImmunobiology
researchProduct

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays

2001

ELISPOT assays are increasingly used for a direct detection and quantification of single antigen-specific T cells in freshly isolated peripheral blood mononuclear cells (PBMC). They are particularly attractive for the monitoring of specific T lymphocyte responses in clinical trials assessing antigen-specific immunizations in patients with cancer or chronic viral infections. However, one major limitation for the broad clinical implementation of ELISPOT assays is the lack of an inexhaustible source of suitable HLA-matched antigen-presenting cells (APC). Currently available allogeneic or xenogeneic APC (such as the human lymphoid hybrid T2 or HLA-transfected insect cells) can either lead to st…

Cytotoxicity ImmunologicImmunoassayAntigen PresentationHLA-A AntigensT cellELISPOTImmunologyStreptamerT lymphocyteCD8-Positive T-LymphocytesBiologyTransfectionSensitivity and SpecificityInterferon-gammaInterleukin 21medicine.anatomical_structureAntigenImmunologymedicineHumansImmunology and AllergyCytotoxic T cellK562 CellsAntigen-presenting cellJournal of Immunological Methods
researchProduct

Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity

2014

Summary Despite development of new antiviral drugs, viral infections are still a major health problem. The most potent antiviral defense mechanism is the innate production of type I interferon (IFN-I), which not only limits virus replication but also promotes antiviral T cell immunity through mechanisms, which remain insufficiently studied. Using the murine lymphocytic choriomeningitis virus model system, we show here that IFN-I signaling on T cells prevented their rapid elimination in vivo. Microarray analyses uncovered that IFN-I triggered the expression of selected inhibitory NK-cell-receptor ligands. Consequently, T cell immunity of IFN-I receptor (IFNAR)-deficient T cells could be rest…

Cytotoxicity ImmunologicImmunologyMedizinReceptor Interferon alpha-betaCD8-Positive T-LymphocytesLymphocytic ChoriomeningitisVirus ReplicationLymphocytic choriomeningitisVirusMiceImmunityInterferonmedicineAnimalsLymphocytic choriomeningitis virusImmunology and AllergyCytotoxic T cellCells CulturedMice KnockoutbiologyPerforinNFIL3medicine.diseaseVirologyImmunity InnateKiller Cells NaturalMice Inbred C57BLBasic-Leucine Zipper Transcription FactorsInfectious DiseasesViral replicationPerforinInterferon Type IImmunologybiology.proteinSignal Transductionmedicine.drugImmunity
researchProduct

In Vivo Protective Effect of Tumour Necrosis Factor   Against Experimental Infection with Herpes Simplex Virus Type 1

1991

C57BL/6 mice, which differ genetically from other strains by their resistance to herpes simplex virus type 1 (HSV-1) infection, were inoculated intraperitoneally with different doses of tumour necrosis factor alpha (TNF-alpha). Mice pretreated with 100 ng, or even 10 ng, of TNF-alpha showed prolonged survival compared to control mice that were infected with 10(7) p.f.u. of HSV-1. Significant protection was observed in mice injected 4 or 8 h prior to or after HSV-1 inoculation, respectively. Protection was also observed when mice which differed at their H-2 locus were treated with TNF-alpha after infection with HSV-1. Interferon could not be detected in the sera of mice at different time poi…

Cytotoxicity ImmunologicTime FactorsNecrosismedicine.medical_treatmentBiologymedicine.disease_causeVirusCell LineNatural killer cellMiceInterferonIn vivoVirologymedicineAnimalsSimplexvirusMice Inbred BALB CTumor Necrosis Factor-alphaHerpes SimplexVirologyRecombinant ProteinsMice Inbred C57BLKineticsHerpes simplex virusCytokinemedicine.anatomical_structureMice Inbred DBAImmunologyTumor necrosis factor alphaInterferonsmedicine.symptommedicine.drugJournal of General Virology
researchProduct

Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.

2013

Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down of T cell activation with ensuing tumor immune escape. While the impact of arginine depletion on polyclonal T cell proliferation and cytokine secretion is well documented, its influence on chemotaxis, cytotoxicity and antigen specific activation of human T cells has not been demonstrated so far. We show here that chemotaxis and early calcium signaling of human T cells are unimpaired in the absence of arginine. We then analyzed CD8(+) T cell activation…

Cytotoxicity Immunologiclcsh:MedicineCD8-Positive T-LymphocytesARGINASELymphocyte ActivationGranzymesInterleukin 21Cytotoxic T cellIL-2 receptorlcsh:ScienceCells CulturedMultidisciplinarybiologyT CellsChemotaxisVaccinationCOFILINCD28Natural killer T cellCANCERmedicine.anatomical_structureMedicineScience & Technology - Other TopicsImmunotherapyResearch ArticleTumor ImmunologyEXPRESSIONINFILTRATING LYMPHOCYTESCARCINOMAGeneral Science & TechnologyT cellImmune CellsImmunologyArginineImmune SuppressionDENDRITIC CELLSImmunomodulationInterferon-gammaMART-1 AntigenMULTIPLE-MYELOMAMD MultidisciplinarymedicineImmune ToleranceHumansCalcium SignalingAntigen-presenting cellBiologyCell ProliferationCD40Science & TechnologyMULTIDISCIPLINARY SCIENCESPerforinlcsh:RImmunityImmunoregulationIN-VITROImmunologic SubspecialtiesMolecular biologybiology.proteinMYELOID SUPPRESSOR-CELLSClinical ImmunologyTumor Escapelcsh:QT-Lymphocytes CytotoxicPLoS ONE
researchProduct

γδ T cell-based anticancer immunotherapy: Progress and possibilities

2015

Cytotoxicity Immunologicmedicine.medical_treatmentT cellT-LymphocytesImmunologyImmunotherapy AdoptiveInterferon-gammaNeoplasmsTumor MicroenvironmentImmunology and AllergyMedicineAnimalsHumansSettore MED/04 - Patologia GeneraleTumor microenvironmentTumor-infiltrating lymphocytesbusiness.industryInterleukin-17Neoplasms therapyReceptors Antigen T-Cell gamma-deltaImmunotherapymedicine.anatomical_structureγδ T cells • cancer • IFN-γ • IL-17 • immunotherapy • PD-1 • tumor-infiltrating lymphocytesOncologyImmunologySettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriobusiness
researchProduct